The study, published in the American Journal of Gastroenterology, analyzed 2.6 million commercial insurance and Medicare Part D claims between May 2022 and April 2023 to monitor how many patients paid out of pocket for bowel prep medications needed for colonoscopy, according to a July 2 news release from the Colon Cancer Coalition, a nonprofit organization.
When considering that almost half of patients are cost-shifted toward the use of non-FDA-approved over-the-counter regimens, the data suggests that only 17% of patients pay nothing for their bowel preparation for screening colonoscopy.
Of the prescription claims analyzed, only 36% had no out-of-pocket costs, according to the release. For Medicare Part D, only 25% of high-volume preps were free.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
